Healthcare / BiotechnologyNasdaqCM
$0.71
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-13.9M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.0%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-20.4M · FCF $-15.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $15062.00 | — |
| Net Income | $-20.4M | $-20.4M | $-13.9M | $-16.0M | $-13.9M | $-2.2M | — |
| EBITDA | $-20.2M | $-20.2M | $-13.6M | $-15.3M | $-12.6M | — | — |
| EPS | — | — | -12.69 | -13.01 | -11.03 | -4.20 | — |
| Gross Margin | — | — | — | — | — | -14.7% | — |
| Operating Margin | — | — | — | — | — | -29925.7% | — |
| Net Margin | — | — | — | — | — | -14430.5% | — |
| Balance Sheet | |||||||
| Debt/Equity | — | — | — | 0.00 | 0.01 | — | — |
| Current Ratio | 35.40 | 35.40 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-15.2M | $-15.2M | $-13.9M | $-13.5M | $-13.8M | $-3.2M | — |
| Returns | |||||||
| ROE | -37.0% | -37.0% | -94.1% | -68.2% | -32.8% | -4.2% | — |
| Valuation | |||||||
| P/B | 0.30 | 0.30 | 0.23 | 0.37 | 0.38 | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | 2.5% | -18.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.69 → n/d
Residual
-26.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.